Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Strides Arcolab
Strides Arcolab
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
Indian Stride Pharma acquires FDA-approved US manufacturing facility
The facility will meet the enhanced capacity needs for soft gels and will offer an alternate site to Strides’ flagship facility in Bangalore
Finance
Strides Shasun acquires three OTC brands from Moberg Pharma
Indian firm is building an over-the-counter drug franchise in regulated and emerging markets
Finance
Sun Pharma to sell Ranbaxy's CNS divisions to Strides Arcolab
Deal is of strategic significance to growth of Strides branded business in India
Finance
Strides to buy drug assets in Australia and Mauritius from Aspen for approximately US$300m
Part of aim to focus on areas where most value can be added, says Strides
Manufacturing
Stelis Biopharma begins construction of US$60m multiproduct biologics facility in Malaysia
Will incorporate the latest single-use bioreactor systems for scale-up and process development
Vietnam bans companies making \'substandard\' drugs
Companies banned include 45 Indian pharmaceutical companies along with others from Korea, France and Pakistan
Finance
US regulators put conditions of Mylan Agila deal
Companies will have to divest 11 generic injectable drugs as a condition of approving the deal
Subscribe now